Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma. However, colon cancer patients harbouring the same BRAF(V600E) oncogenic lesion have poor prognosis and show only a very limited response to this drug. To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tumours, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition. We report that blockade of the epidermal growth factor receptor (EGFR) shows strong synergy with BRAF(V600E) inhibition. We find in multiple BRAF(V600E) mutant colon cancers that inhibition of EGFR by the antibody drug cetuximab or the small-molecule drugs gefitinib or erlotinib is strongly synergistic with BRAF(V600E) inhibition, both in vitro and in vivo. Mechanistically, we find that BRAF(V600E) inhibition causes a rapid feedback activation of EGFR, which supports continued proliferation in the presence of BRAF(V600E) inhibition. Melanoma cells express low levels of EGFR and are therefore not subject to this feedback activation. Consistent with this, we find that ectopic expression of EGFR in melanoma cells is sufficient to cause resistance to PLX4032. Our data suggest that BRAF(V600E) mutant colon cancers (approximately 8-10% of all colon cancers), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibition in BRAFV600 mutant cancers leads to loss of negative feedback signals regulated by the MAPK pathway, leading to receptor tyrosine kinase (RTK)-mediated reactivation of MAPK signaling through wild type RAS and RAF, particularly in specific tumor types, such as colorectal cancer (9–12).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAFV600E cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11,12,32).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This finding is consistent with prior studies identifying HER family and FGFR signaling as key mediators of adaptive feedback to RAS-MAPK pathway inhibitors (10–14,21,22) and recent functional genomic screens(40).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, adaptive feedback resistance has been a key limitation in prior clinical efforts to target the RAS-MAPK pathway.”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [159]
Experimental — accuracy not yet measured
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“shRNA inserts were retrieved from 8mg genomic DNA by PCR amplification (PCR1 and PCR2, see below for primer information) using the following conditions: (1) 98 uC, 30 s; (2) 98 uC, 10 s; (3) 60 uC, 20 s; (4) 72 uC, 1 min; (5) to step (2), 15 cycles; (6) 72 uC, 5 min; (7) 4 uC.”
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“Figure 1e shows that inhibition of EGFR does not significantly affect proliferation of EGFR in WiDr cells, consistent with the clinical observations that KRAS or BRAF mutant CRC cells do not respond to EGFR-targeted monoclonal antibodie”
ResultEpidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,707
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“shRNA inserts were retrieved from 8mg genomic DNA by PCR amplification (PCR1 and PCR2, see below for primer information) using the following conditions: (1) 98 uC, 30 s; (2) 98 uC, 10 s; (3) 60 uC, 20 s; (4) 72 uC, 1 min; (5) to step (2), 15 cycles; (6) 72 uC, 5 min; (7) 4 uC.”
Self-citationThe Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Roth, A. D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., Dietrich, D., Biesmans, B., Bodoky, G., Barone, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3452 · Cited by 1,158
Cited by
Items 901–1,000 of 1,012
Current and Emerging Treatment Paradigms in Colorectal Cancer: Integrating Hallmarks of Cancer
de Torres, C. S., Baraibar, I., Gonzalez, N. S., Ros, J., Salvà, F., Rodríguez-Castells, M., Alcaráz, A., García, A., Tabernero, J. M., & Élez, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136967 · Cited by 29
Realigned transsulfuration drives BRAF-V600E-targeted therapy resistance in melanoma
Borbényi-Galambos, K., Erdélyi, K., Ditrói, T., Jurányi, E. P., Szántó, N., Szatmári, R. Z., Czikora, Á., Schmidt, E. E., Garai, D., Cserepes, M., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.021 · Cited by 28
Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All
Martins, M., Mansinho, A., Cruz-Duarte, R., Lobo-Martins, S., & Costa, L. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02771-1_8 · Cited by 30
Jiang, L., Nie, L., Yan, F., & Yuan, Y. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106460 · Cited by 29
Emerging actionable targets to treat therapy-resistant colorectal cancers
Grassilli, E., & Cerrito, M. G. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.96 · Cited by 33
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
McFall, T. B., Trogdon, M., Guizar, A. C., Langenheim, J. F., Sisk-Hackworth, L., & Stites, E. C. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00329-w · Cited by 29
Morimoto, Y., Yamashita, N., Hirose, H., Fushimi, A., Haratake, N., Daimon, T., Bhattacharya, A., Ahmad, R., Suzuki, Y., Takahashi, H., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216116 · Cited by 26
Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma
Ooki, A., Osumi, H., Fukuda, K., & Yamaguchi, K. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10121-2 · Cited by 26
Epistatic interactions and drug response
Weigelt, B., & Reis-Filho, J. S. (2013) · The Journal of Pathology · doi:10.1002/path.4265 · Cited by 28
Fogliatto, G., Gianellini, L. M., Brasca, M. G., Casale, E., Ballinari, D., Ciomei, M., Degrassi, A., Ponti, A. D., Germani, M., Guanci, M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3512 · Cited by 27
Vemurafenib Treatment ofBRAFV600E-Mutated Malignant Peripheral Nerve Sheath Tumor
Kaplan, H. G. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0173 · Cited by 26
Paul, J. M., Toosi, B. M., Vizeacoumar, F. S., Bhanumathy, K. K., Li, Y., Gerger, C. J., Zawily, A. M. E., Freywald, T., Anderson, D. H., Mousseau, D. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10569 · Cited by 28
Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers
Brauswetter, D., Gurbi, B., Varga, A., Várkondi, E., Schwab, R. B., Bánhegyi, G., Fábián, O., Kéri, G., Valyi-Nagy, I. T., & Peták, I. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185687 · Cited by 29
Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer
Ramroop, J. R., Stein, M. N., & Drake, J. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00028 · Cited by 26
How to find the right drug for each patient? Advances and challenges in pharmacogenomics
Kalamara, A., Tobalina, L., & Sáez-Rodríguez, J. (2018) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2018.07.001 · Cited by 29
Goel, G. (2018) · Cancer Management and Research · doi:10.2147/cmar.s162967 · Cited by 27
Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas
Gao, Y., Vallentgoed, W., & French, P. J. (2018) · Cancers · doi:10.3390/cancers10120489 · Cited by 27
Smith-Cohn, M., Davidson, C. J., Colman, H., & Cohen, A. L. (2019) · CNS Oncology · doi:10.2217/cns-2019-0018 · Cited by 27
Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance
Gonzalez-Martinez, D., Roth, L., Mumford, T. R., Guan, J., Le, A., Doebele, R. C., Huang, B., Tulpule, A., Niewiadomska–Bugaj, M., Bivona, T. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53451-7 · Cited by 26
RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib.
Xu, Z., Hang, J., Hu, J., & Gao, B. (2013) · Europe PMC (PubMed Central) · Cited by 27
Diehl, P., Tedesco, D., & Chenchik, A. A. (2014) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2013.12.002 · Cited by 27
Fujita, Y., Komatsu, N., Matsuda, M., & Aoki, K. (2014) · FEBS Journal · doi:10.1111/febs.12852 · Cited by 30
Cell line modeling for systems medicine in cancers (Review)
KIM, N., He, N., & Yoon, S. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2202 · Cited by 27
Mapping genetic interactions in cancer: a road to rational combination therapies
Tutuncuoglu, B., & Krogan, N. J. (2019) · Genome Medicine · doi:10.1186/s13073-019-0680-4 · Cited by 26
Integrating proteomics into precision oncology
Wahjudi, L. W., Bernhardt, S., Abnaof, K., Horak, P., Kreutzfeldt, S., Heining, C., Borgoni, S., Becki, C., Berg, D., Richter, D., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33301 · Cited by 32
Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma
Czauderna, C., Kirstein, M. M., Tews, H. C., Vogel, A., & Marquardt, J. U. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132803 · Cited by 27
Schouten, P. C., Richters, L., Vis, D. J., Kommoss, S., van Dijk, E., Ernst, C., Kluin, R. J. C., Marmé, F., Lips, E. H., Schmidt, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1673 · Cited by 26
Ali, E. M. H., Mersal, K. I., Ammar, U. M., Zaraei, S., Abdel‐Maksoud, M. S., El–Gamal, M. I., Haque, M. M., Das, T., Kim, E. E., Lee, J., et al. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106115 · Cited by 27
MAP3K Family Review and Correlations with Patient Survival Outcomes in Various Cancer Types
Nguyen, K., Tran, M. N., Rivera, A., Cheng, T., Windsor, G. O., Chabot, A. B., Cavanaugh, J. E., Collins‐Burow, B. M., Lee, S. B., Drewry, D. H., et al. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2705167 · Cited by 28
BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities
Ciner, A., Jiang, Y., & Hausner, P. F. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0626 · Cited by 26
Nelson, B. E., Roszik, J., Jankú, F., Hong, D. S., Kato, S., Naing, A., Piha-Paul, S. A., Fu, S., Tsimberidou, A. M., Cabanillas, M. E., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-022-00341-0 · Cited by 26
Evolution-Informed Strategies for Combating Drug Resistance in Cancer
Lin‐Rahardja, K., Weaver, D. T., Scarborough, J. A., & Scott, J. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076738 · Cited by 25
Gallois, C., Bergen, E. S., Auclin, É., Pernot, S., Higué, J., Trouilloud, I., Touchefeu, Y., Turpin, A., Mazard, T., Bianchi, A. S., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103696 · Cited by 29
Sclafani, F., Iyer, R., Cunningham, D., & Starling, N. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.03.008 · Cited by 26
Climbing RAS, the Everest of Oncogenes
Russo, M., Nicolantonio, F. D., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0906 · Cited by 27
Self-citationBhaskaran, S., Dileep, K. V., Deepa, S. S., Sadasivan, C., Klausner, M., Krishnegowda, N. K., TEKMAL, R. R., VandeBerg, J. L., & Nair, H. B. B. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0965 · Cited by 25
Lucas, F. A. S., Fowler, J., Chang, K., Kopetz, S., Vilar, E., & Scheet, P. A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0260 · Cited by 30
Targeting Mismatch Repair defects: A novel strategy for personalized cancer treatment
Begum, R., & Martin, S. A. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.11.026 · Cited by 26
Neuzillet, C., Rousseau, B., Kocher, H. M., Bourget, P., & Tournigand, C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.028 · Cited by 26
Xue, G., Kohler, R. S., Tang, F., Hynx, D., Wang, Y., Orso, F., Prêtre, V., Ritschard, R., Hirschmann, P., Cron, P. D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18213 · Cited by 26
Biomarker-driven and molecular targeted therapies for colorectal cancers
Schirripa, M., Cohen, S. A., Battaglin, F., & Lenz, H. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.06.003 · Cited by 27
Rational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes
Avolio, M., & Trusolino, L. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1531 · Cited by 26
Changing the Paradigm—Multistage Multiarm Randomized Trials and Stratified Cancer Medicine
Lawler, M., Kaplan, R. S., Wilson, R. H., & Maughan, T. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0014 · Cited by 26
Vougas, K. N., Krochmal, M., Jackson, T., Polyzos, A., Aggelopoulos, A., Pateras, I. S., Liontos, M., Varvarigou, A. A., Johnson, E. O., Georgoulias, V., et al. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/070490 · Cited by 26
Wu, C. S.-Y., & Bekaii‐Saab, T. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/359041 · Cited by 29
Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
Kline, C., & El‐Deiry, W. S. (2013) · Pharmaceuticals · doi:10.3390/ph6080988 · Cited by 26
Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies
Sundar, R., Hong, D. S., Kopetz, S., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0087 · Cited by 28
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS -mutant cancers
Jansen, R. A., Mainardi, S., Dias, M. H., Bosma, A. R., van Dijk, E., Selig, R., Albrecht, W., Laufer, S., Zender, L., & Bernards, R. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2319492121 · Cited by 26
Self-citationColorectal cancer with BRAF V600E mutation: Trends in immune checkpoint inhibitor treatment
Liu, M., Liu, Q., Hu, K., Dong, Y., Sun, X., Zou, Z., Ji, D., Liu, T., & Yu, Y. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104497 · Cited by 25
Anastasi, S., Lamberti, D., Alemà, S., & Segatto, O. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.10.001 · Cited by 24
Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs
Uitdehaag, J. C. M., de Roos, J. A. D. M., van Doornmalen, A. M., Prinsen, M. B. W., Spijkers-Hagelstein, J. A. P., de Vetter, J. R. F., de Man, J., Buijsman, R. C., & Zaman, G. J. R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125021 · Cited by 24
Novel therapeutic agents in the treatment of metastatic colorectal cancer
Pai, S. G., & Fuloria, J. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i1.99 · Cited by 25
Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells
Bosch-Vilaró, A., Jacobs, B., Pomella, V., Asbagh, L. A., Kirkland, R. E., Michel, J., Singh, S., Liu, X., Kim, P., Weitsman, G. E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13834 · Cited by 26
Withania somnifera Root Extract Enhances Chemotherapy through ‘Priming’
Henley, A. B., Yang, L., Chuang, K.-L., Sahuri-Arisoylu, M., Wu, L.-H., Bligh, S. W. A., & Bell, J. D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170917 · Cited by 24
The Pros and Cons of Incorporating Transcriptomics in the Age of Precision Oncology
Lin, V. T. G., & Yang, E. S.-H. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz114 · Cited by 27
Huijberts, S. C. F. A., van Geel, R. M. J. M., Bernards, R., Beijnen, J. H., & Steeghs, N. (2020) · Future Oncology · doi:10.2217/fon-2019-0748 · Cited by 26
Self-citationWhiteaker, J. R., Sharma, K., Hoffman, M. A., Kuhn, E. W., Zhao, L., Cocco, A. R., Schoenherr, R. M., Kennedy, J. J., Voytovich, U. J., Lin, C., et al. (2021) · Cell Reports Methods · doi:10.1016/j.crmeth.2021.100015 · Cited by 27
Current controversies in the management of metastatic colorectal cancer
Vera, R., Alonso, V., Gallego-Plazas, J., González‐Flores, E., Guillén‐Ponce, C., Pericay, C., Rivera, F., Safont, M. J., & Valladares‐Ayerbes, M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2808-6 · Cited by 25
Article Commentary: Predictive Modeling of Drug Treatment in the Area of Personalized Medicine
Ogilvie, L. A., Wierling, C., Kessler, T., Lehrach, H., & Lange, B. M. H. (2015) · Cancer Informatics · doi:10.4137/cin.s19330 · Cited by 24
Vaishnavi, A., Scherzer, M. T., Kinsey, C. G., Parkman, G. L., Truong, A., Ghazi, P., Schuman, S., Battistone, B., Garrido-Laguna, I., & McMahon, M. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107994 · Cited by 23
“Feedback inhibition from the MAPK pathway to EGFR following targeted therapy has been previously observed in different tissues and contexts (Lito et al., 2012; Prahallad et al., 2012).”
BackgroundImpact of tumor sequencing on the use of anticancer drugs
Thomas, F., Desmedt, C., Aftimos, P. G., & Awada, A. H. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000078 · Cited by 25
Targeted therapies of solid cancers: new options, new challenges
Awada, A. H., & Aftimos, P. G. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835ff318 · Cited by 25
Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation
Virzì, A. R., Gentile, A., Benvenuti, S., & Comoglio, P. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1721147115 · Cited by 23
Engineering Multidimensional Evolutionary Forces to Combat Cancer
McCoach, C. E., & Bivona, T. G. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1196 · Cited by 25
Sasankan, S., Rebuck, L., Darrah, G., Harari-Turquie, M., & Rabinowitz, I. (2020) · Case Reports in Oncology · doi:10.1159/000510096 · Cited by 23
Lee, C.-I., Liao, C., Chen, C.-S., Cheng, F., Chung, Y.-H., Wang, Y.-C., Ciou, S.-Y., Hsueh, W.-Y., Lo, T.-H., Huang, G.-R., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104715 · Cited by 23
Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors
Heynen, G. J. J. E., Lisek, K., Vogel, R., Wulf-Goldenberg, A., Alcaniz, J., Montaudon, É., Marangoni, E., & Birchmeier, W. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01521-3 · Cited by 23
He, R. X., Zhang, M., He, L., Huang, J., Man, C., Wang, X., Lang, Y., & Fan, Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.845271 · Cited by 25
Al-Wahaibi, L. H., El‐Sheref, E. M., Hassan, A. A., Bräse, S., Nieger, M., Youssif, B. G. M., Ibrahim, M. A. A., & Tawfeek, H. N. (2023) · Pharmaceuticals · doi:10.3390/ph16071014 · Cited by 23
Sale, M. J., & Cook, S. J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12220 · Cited by 20
The spectrum of clinical trials aiming at personalizing medicine.
Tourneau, C. L., Kamal, M. T., Alt, M., Verlingue, L., Servois, V., Sablin, M., Servant, N., & Paolettí, X. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.05.02 · Cited by 24
Diverse array-designed modes of combination therapies in Fangjiomics
Liu, J. H., & Wang, Z. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.125 · Cited by 23
Essential role of AKT in tumor cells addicted to FGFR
Hu, Y., Lu, H., Zhang, J., Chen, J., Chai, Z., & Zhang, J. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000034 · Cited by 23
Finding effective cancer therapies through loss of function genetic screens
Bernards, R. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.007 · Cited by 23
Self-citationData resources for the identification and interpretation of actionable mutations by clinicians
Prawira, A., Pugh, T. J., Stockley, T. L., & Siu, L. L. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx023 · Cited by 25
Evolutionary dynamics and significance of multiple subclonal mutations in cancer
Beckman, R. A., & Loeb, L. A. (2017) · DNA repair · doi:10.1016/j.dnarep.2017.06.002 · Cited by 27
Koplev, S., Longden, J., Ferkinghoff‐Borg, J., Bjerregård, M. B., Cox, T. R., Erler, J. T., Pedersen, J. T., Völlmy, F., Sommer, M. O. A., & Linding, R. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.095 · Cited by 26
Considerations for Developing Targeted Therapies in Low‐Frequency Molecular Subsets of a Disease
Schuck, R. N., Woodcock, J., Zineh, I., Stein, P., Jarow, J. P., Temple, R., Permutt, T., LaVange, L. M., Beaver, J. A., Charlab, R., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1041 · Cited by 24
Sahasrabudhe, N. M., Lenos, K., van der Horst, J. C., Rodríguez, E., & van Vliet, S. J. (2018) · Biological Chemistry · doi:10.1515/hsz-2018-0120 · Cited by 23
Dankner, M. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00195 · Cited by 24
Baur, F., Nietzer, S., Kunz, M., Saal, F., Jeromin, J., Matschos, S., Linnebacher, M., Walles, H., Dandekar, T., & Dandekar, G. (2019) · Cancers · doi:10.3390/cancers12010028 · Cited by 24
Park, S., Hwang, C. Y., Choi, J., Joung, C. Y., & Cho, K. (2020) · Oncogene · doi:10.1038/s41388-020-1255-y · Cited by 26
Seghers, A.-K., Cuyle, P.-J. A., & Cutsem, E. V. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00727-9 · Cited by 24
Clinical Update: Colon, Rectal, and Anal Cancers
Wilkes, G. M., & Hartshorn, K. L. (2012) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2012.09.012 · Cited by 28
García-García, C., Rivas, M. A., Ibrahim, Y. H., Calvo, M. T., Gris‐Oliver, A., Rodríguez, O., Grueso, J., Antón, P., Guzmán, M., Aura, C. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3091 · Cited by 26
Optimization of personalized therapies for anticancer treatment
Vázquez, A. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-31 · Cited by 23
Yang, M., Davis, T. B., Pflieger, L., Nebozhyn, M. V., Loboda, A., Wang, H., Schell, M. J., Thota, R., Pledger, W. J., & Yeatman, T. J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09344-3 · Cited by 22
“This suggested that, in contrast to that observed with BRAFi treatments [9, 11], MEKi may mediate AR by a mechanism independent of EGFR.”
BackgroundResultDing, X., Huang, H., Zhang, F., & Jiang, J. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01282-5 · Cited by 28
Ma, R., Xu, L., Qu, X., Che, X., Zhang, Y., Fan, Y., Li, C., Guo, T., Hou, K., Hu, X., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0086-x · Cited by 22
Tailored Systemic Therapy for Colorectal Cancer Liver Metastases
Czauderna, C., Luley, K. B., von Bubnoff, N. C. C., & Marquardt, J. U. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111780 · Cited by 23
Raman, R., Villefranc, J. A., Ullmann, T. M., Thiesmeyer, J. W., Anelli, V., Yao, J., Hurley, J. R., Pauli, C., Bareja, R., Eng, K., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20210390 · Cited by 22
Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies
Akkad, J., Bochum, S., & Martens, U. M. (2015) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-015-1276-0 · Cited by 24
Hirschi, B., Gallmeier, E., Ziesch, A., Marschall, M. K., & Kolligs, F. T. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-122 · Cited by 27
Integrative radiation systems biology
Unger, K. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-21 · Cited by 23
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors
Stewart, A., Thavasu, P., Bono, J. S. D., & Banerji, U. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv188 · Cited by 24
Functional interplay between secreted ligands and receptors in melanoma
Herráiz, C., Jiménez‐Cervantes, C., Sánchez‐Laorden, B. L., & García-Borrón, J. C. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.06.021 · Cited by 23
Colorectal cancer genomics and designing rational trials
Mondaca, S., & Yaeger, R. D. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.27 · Cited by 23
Dovrat, T. O., Sokol, E. S., Frampton, G. M., Shachar, E. K., Pelles, S., Geva, R., & Wolf, I. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1480289 · Cited by 25
Ros, J., Baraibar, I., Martini, G., Salvà, F., Gonzalez, N. S., Cuadra‐Urteaga, J. L., Dienstmann, R., Tabernero, J. M., & Élez, E. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00913-5 · Cited by 25
Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.483 · Cited by 21
Metadata
- Authors
- Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of Turin (IT)
- IFOM (IT)
- Corresponding author
- Bernards, René
- ORCID
- Venue
- Nature
- Published
- 2012-01-26
- Volume
- 483
- Issue
- 7387
- Pages
- 100-103
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2014881369
- Semantic Scholar
- 10564d8dc4a3ddb05a84b5a3ca8b7b622c5c17ea
- Cited by
- 2,051
- References
- 22
- Citations by year
- 2026: 75 · 2025: 81 · 2024: 106 · 2023: 145 · 2022: 126 · 2021: 168 · 2020: 145 · 2019: 117 · 2018: 139 · 2017: 129 · 2016: 149 · 2015: 215 · 2014: 188 · 2013: 172 · 2012: 91
- FWCI
- 105.49
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- European Commission (259015)
- Ministero della Salute
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- KWF Kankerbestrijding
- Associazione Italiana per la Ricerca sul Cancro (5 x mille)
- Regione Piemonte
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- BRAF V600E mutation, colon cancer, EGFR, vemurafenib, drug resistance, feedback activation, cetuximab, gefitinib, erlotinib, combination therapy, RNAi screen, melanoma, targeted therapy
- MeSH terms
- Cetuximab, Erlotinib Hydrochloride, Gefitinib, Vemurafenib, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Drug Synergism, Enzyme Activation, Female, Humans, Indoles, Melanoma, Quinazolines, Sulfonamides, Colorectal Neoplasms, Apoptosis, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Feedback, Physiological, RNA Interference, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, HEK293 Cells, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.